A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial

British Journal of Dermatology

Volumn 168, Issue 2, 2013, Pages 444-446

  Tsai, T F ^a   Chiu, H Y ^a   Song, M ^b   Chan, D ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; USTEKINUMAB;

AGED; ANTIBIOTIC THERAPY; CASE REPORT; CHEMOPROPHYLAXIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; LATENT TUBERCULOSIS; LETTER; MALE; MYCOBACTERIUM TUBERCULOSIS; PHOTOTHERAPY; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; THORAX RADIOGRAPHY; TUBERCULIN TEST; UNSPECIFIED SIDE EFFECT;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTITUBERCULAR AGENTS; DERMATOLOGIC AGENTS; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; PSORIASIS; TUBERCULOSIS, PULMONARY;

EID: 84873157165     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11162.x     Document Type: Letter

References (8)

1. Reich K, Papp K, Griffiths CEM, et al. PHOENIX 1, PHOENIX 2, and ACCEPT study investigators. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to 4 years of follow-up. J Drugs Dermatol 2012; 11: 300-12.
2. Tsai T-F, Ho J-C, Song M, et al. PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-63.
3. Igarashi A, Kato T, Kato M, et al. Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-52.
4. Zheng M, Zhu X, Song M, et al. A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results. World Psoriasis and Psoriatic Arthritis 2012 Conference; Abstract 2497069.
5. Tsai T-F, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; doi: 10.1111/j.1365-2133.2012.11142.x. [Epub ahead of print].
6. Chiu H-Y, Hsueh P-R, Tsai T-F,. Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011; 164: 553-9.
7. Binymin K, Cooper RG,. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 341-2.
8. Benson J, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011; 3: 535-45.